Cited by 359Advanced Drug Delivery SystemsInhalation and Respiratory Drug DeliveryHead and Neck Surgical Oncology

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Insights into direct nose to brain delivery: current status and future perspective

Open access

Mittal, Deepti, Ali, Asgar, Md, Shadab, Baboota, Sanjula, Sahni, Jasjeet K., Ali, Javed·2014·Drug Delivery

DOI 10.3109/10717544.2013.838713

Open this paper in CoChat — free account Open PDF

Abstract

Now a day's intranasal (i.n) drug delivery is emerging as a reliable method to bypass the blood-brain barrier (BBB) and deliver a wide range of therapeutic agents including both small and large molecules, growth factors, viral vectors and even stem cells to the brain and has shown therapeutic effects in both animals and humans. This route involves the olfactory or trigeminal nerve systems which initiate in the brain and terminate in the nasal cavity at the olfactory neuroepithelium or respiratory epithelium. They are the only externally exposed portions of the central nervous system (CNS) and therefore represent the most direct method of noninvasive entry into the brain. This approach has been primarily used to explore therapeutic avenues for neurological diseases. The potential for treatment possibilities with olfactory transfer of drugs will increase as more effective formulations and delivery devices are developed. Recently, the apomorphine hydrochloride dry powders have been developed for i.n. delivery (Apomorphine nasal, Lyonase technology, Britannia Pharmaceuticals, Surrey, UK). The results of clinical trial Phase III suggested that the prepared formulation had clinical effect equivalent to subcutaneously administered apomorphine. In coming years, intranasal delivery of drugs will demand more complex and automated delivery devices to ensure accurate and repeatable dosing. Thus, new efforts are needed to make this noninvasive route of delivery more efficient and popular, and it is also predicted that in future a range of intranasal products will be used in diagnosis as well as treatment of CNS diseases. This review will embark the existing evidence of nose-to-brain transport. It also provides insights into the most relevant pre-clinical studies of direct nose-brain delivery and delivery devices which will provide relative success of intranasal delivery system. We have, herein, outlined the relevant aspects of CNS drugs given intranasally to direct the brain in treating CNS disorders like Alzheimer's disease, depression, migraine, schizophrenia, etc.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3109/10717544.2013.838713

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,978
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., Itri, L. M., & Cerami, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.19.10526 · Cited by 1,402
Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239
A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes
Letchford, K., & Burt, H. M. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.11.009 · Cited by 1,200
Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors
Bymaster, F. P. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 725
Intranasal Drug Delivery: How, Why and What For?
Pires, A., Fortuna, A., Alves, G., & Falcão, A. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3nc79 · Cited by 641
Effect of chitosan on epithelial permeability and structure
Dodane, V. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00030-7 · Cited by 579
Triptans in Migraine
Tfelt‐Hansen, P. C., de Vries, P. W., & Saxena, P. R. (2000) · Drugs · doi:10.2165/00003495-200060060-00003 · Cited by 536
Nanotechnological advances for the delivery of cns therapeutics.
Wong, H. L., Wu, X. Y., & Bendayan, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.007 · Cited by 488

Show all 70 references

Research works printed but not linked: 5

Dhanda DS, 2005, Drug Del Tech, 5, 64
Ghigo E, 1994, J Clin Endocrinol Metab, 78, 693
Jenner P, 1986, Adv Neurol, 43, 629
Mustafa G, 2012, Curr Nanosci, 29, 293
Putheti R, 2009, J Sci Tec, 4, 1

Sorted by citations

Nanostructured lipid carriers for site-specific drug delivery
Khosa, A., Reddi, S., & Saha, R. N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.055 · Cited by 622
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa
Gänger, S., & Schindowski, K. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030116 · Cited by 447
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics
Bourganis, V., Kammona, O., Alexopoulos, A., & Kiparissides, C. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.05.009 · Cited by 357
Blood-brain barrier regulation in psychiatric disorders
Kealy, J., Greene, C., & Campbell, M. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.06.033 · Cited by 318
Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease
Fonseca‐Santos, B., Chorilli, M., & Gremião, M. P. D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87148 · Cited by 320
Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies
Costa, C. P., Moreira, J. N., Lobo, J. M. S., & Silva, A. C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.012 · Cited by 317
Stimuli-responsive In situ gelling system for nose-to-brain drug delivery
Agrawal, M., Saraf, S., Saraf, S., Dubey, S. K., Puri, A., Gupta, U. D., Kesharwani, P., Ravichandiran, V., Kumar, P., Naidu, V. G. M., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.044 · Cited by 304
Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases
Meredith, M. E., Salameh, T. S., & Banks, W. A. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9719-7 · Cited by 231
Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges
Chatterjee, B., Gorain, B., Mohananaidu, K., Sengupta, P., Mandal, U. K., & Choudhury, H. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.05.032 · Cited by 223
RETRACTED: Solid lipid nanoparticle-based dissolving microneedles: A promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis
Permana, A. D., Tekko, I. A., McCrudden, M., Anjani, Q. K., Ramadon, D., McCarthy, H. O., & Donnelly, R. F. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.004 · Cited by 211
Retracted
Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting
Selvaraj, K., Kuppusamy, G., & Karri, V. V. S. R. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1420073 · Cited by 211
Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier
Lee, D., & Minko, T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122049 · Cited by 227
Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis
Costa, C. P., Moreira, J. N., Amaral, M. H., Lobo, J. M. S., & Silva, A. C. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.049 · Cited by 216
Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood–brain barrier (BBB) to manage neurological disorders
Correia, A. D. A., Monteiro, A. R., Silva, R., Moreira, J. N., Lobo, J. M. S., & Silva, A. C. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114485 · Cited by 219
Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery
Battaglia, L., Panciani, P., Muntoni, E., Capucchio, M., Biasibetti, E., Bonis, P. D., Mioletti, S., Fontanella, M., & Swaminathan, S. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1429401 · Cited by 185
Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson’s disease by reducing oxidative stress
Pangeni, R., Sharma, S., Mustafa, G., Ali, J., & Baboota, S. (2014) · Nanotechnology · doi:10.1088/0957-4484/25/48/485102 · Cited by 192
Self-citation
Olfactory deposition of inhaled nanoparticles in humans
Garcia, G. J. M., Schroeter, J. D., & Kimbell, J. S. (2015) · Inhalation Toxicology · doi:10.3109/08958378.2015.1066904 · Cited by 191
Electronic nose: a non-invasive technology for breath analysis of diabetes and lung cancer patients
Behera, B., Joshi, R., Anil Vishnu, G. K., Bhalerao, S., & Pandya, H. J. (2019) · Journal of Breath Research · doi:10.1088/1752-7163/aafc77 · Cited by 179
Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
Andrade, S., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01261 · Cited by 173
“This molecule increases the expression of some antioxidant enzymes in the brain of healthful animals and presents an excellent antioxidant effect (Mokni et al., 2007).”
Background
Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders
Bahadur, S., Pardhi, D. M., Rautio, J., Rosenholm, J. M., & Pathak, K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121230 · Cited by 178
Nose to brain drug delivery - A promising strategy for active components from herbal medicine for treating cerebral ischemia reperfusion
Long, Y., Yang, Q., Xiang, Y., Zhang, Y., Wan, J., Liu, S., Li, N., & Peng, W. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104795 · Cited by 151
Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery
Alex, A. T., Joseph, A., Shavi, G. V., Rao, J. V., & Udupa, N. (2014) · Drug Delivery · doi:10.3109/10717544.2014.948643 · Cited by 151
Nasal Delivery to the Brain: Harnessing Nanoparticles for Effective Drug Transport
Gandhi, S. J., Shastri, D. H., Shah, J., Nair, A. B., & Jacob, S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040481 · Cited by 162
Cubosomes as an emerging platform for drug delivery: a review of the state of the art
Abourehab, M. A. S., Ansari, M. J., Singh, A., Hassan, A., Abdelgawad, M. A., Shrivastav, P., Abualsoud, B. M., Amaral, L. S., & Pramanik, S. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00031h · Cited by 143
Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery
Sarvaiya, J., & Agrawal, Y. K. (2014) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2014.08.052 · Cited by 140
Chitosan-Coated Nanoparticles: Effect of Chitosan Molecular Weight on Nasal Transmucosal Delivery
Bruinsmann, F. A., Pigana, S., Aguirre, T. A. S., Souto, G. D., Pereira, G. G., Bianchera, A., Fasiolo, L. T., Colombo, G., Marques, M. D. S., Pohlmann, A. R., et al. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020086 · Cited by 140
Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders
Md, S., Bhattamisra, S. K., Zeeshan, F., Shahzad, N., Mujtaba, M. A., Meka, V. S., Radhakrishnan, A. K., Kesharwani, P., Baboota, S., & Ali, J. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.09.022 · Cited by 140
Self-citation
In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases
Aderibigbe, B. A. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020040 · Cited by 133
Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion
Abdou, E. M., Kandil, S. M., & Miniawy, H. M. F. E. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.030 · Cited by 124
Development of risperidone liposomes for brain targeting through intranasal route
Narayan, R., Singh, M., Ranjan, O. P., Nayak, Y., Garg, S., Shavi, G. V., & Nayak, U. Y. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.08.033 · Cited by 118
Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route
Mittal, D., Md, S., Hasan, Q., Fazil, M., Ali, A., Baboota, S., & Ali, J. (2014) · Drug Delivery · doi:10.3109/10717544.2014.907372 · Cited by 120
Self-citation
Research progress in brain-targeted nasal drug delivery
Huang, Q., Chen, X., Yu, S., Gong, G., & Shu, H. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1341295 · Cited by 136
Application of Box-Behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route
Shah, B., Khunt, D., Misra, M., & Padh, H. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.04.076 · Cited by 112
Optimization of Nanostructured Lipid Carriers of Lurasidone Hydrochloride Using Box-Behnken Design for Brain Targeting: In Vitro and In Vivo Studies
Jazuli, I., Annu, Nabi, B., Moolakkadath, T., Alam, T., Baboota, S., & Ali, J. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.001 · Cited by 117
Self-citation
Engineered commensals for targeted nose-to-brain drug delivery
Shen, H., Aggarwal, N., Cui, B., Foo, G. W., He, Y., Srivastava, S. K., Li, S., Seah, M. Z. X., Wun, K. S., Ling, H., et al. (2025) · Cell · doi:10.1016/j.cell.2025.01.017 · Cited by 119
Recent progress in nanocarriers for direct nose to brain drug delivery
Emad, N. A., Ahmed, B., Alhalmi, A., Alzobaidi, N., & Al-Kubati, S. S. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102642 · Cited by 114
Memantine nanoemulsion: a new approach to treat Alzheimer’s disease
Kaur, A., Nigam, K., Srivastava, S., Tyagi, A. K., & Dang, S. (2020) · Journal of Microencapsulation · doi:10.1080/02652048.2020.1756971 · Cited by 106
Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal/Intraspinal, and Intra-Articular
Emami, A., Tepper, J., Short, B. G., Yaksh, T. L., Bendele, A. M., Ramani, T., Cisternas, A. F., Chang, J., & Mellon, R. D. (2017) · International Journal of Toxicology · doi:10.1177/1091581817741840 · Cited by 97
Non-Invasive Strategies for Nose-to-Brain Drug Delivery.
Ja, T., Quispe, R. C., Khan, F. A., & Новак (2020) · PubMed · Cited by 114
Rasagiline-encapsulated chitosan-coated PLGA nanoparticles targeted to the brain in the treatment of parkinson's disease
Ahmad, N. (2017) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2017.1343735 · Cited by 97
Improved In Vitro Model for Intranasal Mucosal Drug Delivery: Primary Olfactory and Respiratory Epithelial Cells Compared with the Permanent Nasal Cell Line RPMI 2650
Ladel, S., Schlossbauer, P., Flamm, J., Luksch, H., Mizaikoff, B., & Schindowski, K. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11080367 · Cited by 96
Different Methods and Formulations of Drugs and Vaccines for Nasal Administration
Tai, J., Han, M. S., Lee, D., Park, I., Lee, S. H., & Kim, T. H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051073 · Cited by 104
Intranasal drug delivery for treatment of Alzheimer’s disease
Fonseca, L., Lopes, J. A., Vieira, J., Viegas, C., Oliveira, C. S., Hartmann, R. P., & Fonte, P. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00940-7 · Cited by 93
Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration
Shah, B. M., Khunt, D., Misra, M., & Padh, H. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.05.008 · Cited by 93
Brain Signaling Systems in the Type 2 Diabetes and Metabolic Syndrome: Promising Target to Treat and Prevent These Diseases
Shpakov, A. O., Derkach, K. V., & Berstein, L. M. (2015) · Future Science OA · doi:10.4155/fso.15.23 · Cited by 93
Biomaterials-Enhanced Intranasal Delivery of Drugs as a Direct Route for Brain Targeting
Marcello, E., & Chiono, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043390 · Cited by 88
Brain delivery of buspirone hydrochloride chitosan nanoparticles for the treatment of general anxiety disorder
Bari, N. K., Fazil, M., Hassan, M. Q., Haider, M. R., Gaba, B., Narang, J. K., Baboota, S., & Ali, J. (2015) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.07.041 · Cited by 83
Self-citation
Intracellular cholesterol trafficking is dependent upon NPC2 interaction with lysobisphosphatidic acid
McCauliff, L. A., Langan, A., Li, R., Ilnytska, O., Bose, D., Waghalter, M., Lai, K., Kahn, P. C., & Storch, J. (2019) · eLife · doi:10.7554/elife.50832 · Cited by 82
Nanoneurotherapeutics approach intended for direct nose to brain delivery
Md, S., Mustafa, G., Baboota, S., & Ali, J. (2015) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2015.1052081 · Cited by 78
Self-citation
Optimization of Curcumin Nanocrystals as Promising Strategy for Nose-to-Brain Delivery Application
Bonaccorso, A., Gigliobianco, M. R., Pellitteri, R., Santonocito, D., Carbone, C., Martino, P. D., Puglisi, G., & Musumeci, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050476 · Cited by 79
Dihydroergotamine (DHE) – Then and Now: A Narrative Review
Silberstein, S. D., Shrewsbury, S. B., & Hoekman, J. (2019) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13700 · Cited by 76
A comparison study of lipid and polymeric nanoparticles in the nasal delivery of meloxicam: Formulation, characterization, and in vitro evaluation
Akel, H., Ismail, R., Katona, G., Sabir, F., Ambrus, R., & Csóka, I. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120724 · Cited by 80
Nose-to-brain delivery of levetiracetam after intranasal administration to mice
Gonçalves, J., Bicker, J., Gouveia, F., Liberal, J. M. T., Oliveira, R. C., Alves, G., Falcão, A. C., & Fortuna, A. C. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.04.047 · Cited by 72
Management of epileptic disorders using nanotechnology-based strategies for nose-to-brain drug delivery
Shringarpure, M., Gharat, S., Momin, M. M., & Omri, A. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1823965 · Cited by 70
Using nanotechnology to deliver biomolecules from nose to brain — peptides, proteins, monoclonal antibodies and RNA
Borrajo, M. L., & Alonso, M. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01086-2 · Cited by 76
Targeting Small Molecule Delivery to the Brain and Spinal Cord via Intranasal Administration of Rabies Virus Glycoprotein (RVG29)-Modified PLGA Nanoparticles
Chung, E. P., Cotter, J. D., Prakapenka, A. V., Cook, R. L., DiPerna, D. M., & Sirianni, R. W. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020093 · Cited by 70
Nose-to-brain drug delivery mediated by polymeric nanoparticles: influence of PEG surface coating
de Oliveira, E. R., dos Santos, L. C. R., Salomão, M. A., Nascimento, T. L., Oliveira, G. D. A. R., Lião, L. M., & Lima, E. M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00816-2 · Cited by 69
Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease
Linares, G. R., Chiu, C., Scheuing, L., Leng, Y., Liao, H., Maric, D., & Chuang, D. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.04.003 · Cited by 69
Behavioral impairments following repeated intranasal glyphosate-based herbicide administration in mice
Baier, C. J., Gallegos, C. E., Raisman‐Vozari, R., & Minetti, A. (2017) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2017.10.004 · Cited by 71
RVG29-modified microRNA-loaded nanoparticles improve ischemic brain injury by nasal delivery
Hao, R., Sun, B., Yang, L., Ma, C., & Li, S. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1760960 · Cited by 68
Targeted delivery of intranasally administered nanoparticles-mediated neuroprotective peptide NR2B9c to brain and neuron for treatment of ischemic stroke
Li, R., Huang, Y., Chen, L., Zhou, H.-H., Zhang, M., Chang, L., Shen, H. Y., Zhou, M., Su, P., & Zhu, D. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.10.013 · Cited by 68
Improving the Brain Delivery of Chemotherapeutic Drugs in Childhood Brain Tumors
Triarico, S., Maurizi, P., Mastrangelo, S., Attinà, G., Capozza, M. A., & Ruggiero, A. (2019) · Cancers · doi:10.3390/cancers11060824 · Cited by 67
SIRT1 and stem cells: In the forefront with cardiovascular disease, neurodegeneration and cancer
Maiese, K. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i2.235 · Cited by 67
Nose-to-brain delivery of antipsychotics using nanotechnology: a review
Tan, M. S. A., Parekh, H. S., Pandey, P. M., Siskind, D. J., & Falconer, J. R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1762563 · Cited by 68
Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia
Ahmad, N., Ahmad, R., Alam, A., & Ahmad, F. J. (2018) · Drug Research · doi:10.1055/a-0596-7288 · Cited by 65
Clozapine loaded nanostructured lipid carriers engineered for brain targeting via nose-to-brain delivery: Optimization and in vivo pharmacokinetic studies
Patel, H., Gandhi, P. A., Chaudhari, P. S., Desai, B. V., Desai, D. T., Dedhiya, P. P., Maulvi, F. A., & Vyas, B. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102533 · Cited by 64
Neurodegenerative disorders management: state-of-art and prospects of nano-biotechnology
Kumar, R., Aadil, K. R., Mondal, K., Mishra, Y. K., Oupický, D., Ramakrishna, S., & Kaushik, A. K. (2021) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2021.1993126 · Cited by 64
Modulating chitosan-PLGA nanoparticle properties to design a co-delivery platform for glioblastoma therapy intended for nose-to-brain route
Ferreira, N. N., Granja, S., Boni, F. I., Prezotti, F. G., Ferreira, L. M. B., Cury, B. S. F., Reis, R. M., Baltazar, F., & Gremião, M. P. D. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00824-2 · Cited by 61
Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery
Rukmangathen, R., Muzib, Y. I., & Yalavarthi, P. R. (2019) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1619759 · Cited by 61
Pharmacokinetics, pharmacodynamics and toxicity of Baicalin liposome on cerebral ischemia reperfusion injury rats via intranasal administration
Yan, X., Long, Y., Yang, Q., Zheng, C., Cui, M., Ci, Z., Lv, X.-M., Li, N., & Zhang, R. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146503 · Cited by 57
Modulation of midbrain neurocircuitry by intranasal insulin
Edwin Thanarajah, S., Iglesias, S., Kuzmanovic, B., Rigoux, L., Stephan, K. E., Brüning, J. C., & Tittgemeyer, M. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.03.050 · Cited by 55
Regeneration in the nervous system with erythropoietin
Maiese, K. (2015) · Frontiers in bioscience · doi:10.2741/4408 · Cited by 54
Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice.
Chauhan, M., & Chauhan, N. B. (2015) · PubMed · Cited by 55
Sesame Oil-Based Nanostructured Lipid Carriers of Nicergoline, Intranasal Delivery System for Brain Targeting of Synergistic Cerebrovascular Protection
Abourehab, M. A. S., Khames, A., Genedy, S., Mostafa, S., Khaleel, M. A., Omar, M. M., & Sisi, A. M. E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040581 · Cited by 56
Development of a microemulsion for encapsulation and delivery of gallic acid. The role of chitosan
Mitsou, E., Pletsa, V., Sotiroudis, G. T., Panine, P., Zoumpanioti, M., & Xenakis, A. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.110974 · Cited by 55
Alzheimer’s Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology
Agarwal, M., Alam, R., Haider, M. K., Malik, M. Z., & Kim, D.-K. (2020) · Nanomaterials · doi:10.3390/nano11010059 · Cited by 59
Inflammatory signaling pathways in the treatment of Alzheimer's disease with inhibitors, natural products and metabolites (Review)
Zheng, Y., Zhang, X., Zhang, R., Wang, Z., Gan, J., Gao, Q., Yang, L., Xu, P., & Jiang, X. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5314 · Cited by 52
Effects of Intranasal Administration of Oxytocin and Vasopressin on Social Cognition and Potential Routes and Mechanisms of Action
Yao, S., & Kendrick, K. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020323 · Cited by 55
Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer’s disease in intracerebroventricular streptozotocin model for brain delivery
Zameer, S., Ali, J., Vohora, D., Najmi, A. K., & Akhtar, M. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1817041 · Cited by 51
Self-citation
Urban airborne PM2.5-activated microglia mediate neurotoxicity through glutaminase-containing extracellular vesicles in olfactory bulb
Chen, X., Guo, J., Huang, Y., Liu, S., Huang, Y., Zhang, Z., Zhang, F., Lu, Z., Li, F., Zheng, J., et al. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2020.114716 · Cited by 49
Development of Imatinib Mesylate-Loaded Liposomes for Nose to Brain Delivery: In Vitro and In Vivo Evaluation
Saka, R., Chella, N., & Khan, W. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-021-02072-0 · Cited by 50
In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose‐to‐brain drug delivery
Haasbroek‐Pheiffer, A., Niekerk, S. E. V., van der Kooy, F., Cloete, T. T., Steenekamp, J. H., & Hamman, J. H. (2023) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2348 · Cited by 51
Dry Powder Inhaler with the technical and practical obstacles, and forthcoming platform strategies
Gaikwad, S. S., Pathare, S. R., More, M. A., Waykhinde, N. A., Laddha, U. D., Salunkhe, K. S., Kshirsagar, S. J., Patil, S. S., & Ramteke, K. H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.083 · Cited by 48
How does oxytocin modulate human behavior?
Yao, S., & Kendrick, K. M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02898-1 · Cited by 61
Applications of the Keap1–Nrf2 system for gene and cell therapy
Kanninen, K. M., Pomeshchik, Y., Leinonen, H. M., Malm, T., Koıstınaho, J., & Levonen, A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.037 · Cited by 47
Formulating SLN and NLC as Innovative Drug Delivery Systems for Non-Invasive Routes of Drug Administration
Fonseca‐Santos, B., da Silva, P. B., Rigon, R. B., Sato, M. R., & Chorilli, M. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867326666190624155938 · Cited by 47
Nose-to-brain drug delivery for the treatment of Alzheimer’s disease: current advancements and challenges
Prabakaran, A., Agrawal, M., Dethe, M. R., Ahmed, H., Yadav, A. K., Gupta, U. D., & Alexander, A. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2029845 · Cited by 47
Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases
Chen, T., Fonseca, C. D., & Schönthal, A. H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091463 · Cited by 46
The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems
Fonseca‐Santos, B., & Chorilli, M. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119832 · Cited by 47
Nose to brain delivery of tailored clozapine nanosuspension stabilized using (+)-alpha-tocopherol polyethylene glycol 1000 succinate: Optimization and in vivo pharmacokinetic studies
Patel, H., Chaudhari, P. S., Gandhi, P. A., Desai, B. V., Desai, D. T., Dedhiya, P. P., Vyas, B., & Maulvi, F. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120474 · Cited by 47
Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients
Jin, Z., Han, Y., Zhang, D., Li, Z., Jing, Y., Hu, B., & Sun, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102070 · Cited by 45
Nose-to-brain drug delivery for the treatment of CNS disease: New development and strategies
Du, L., Chen, L., Liu, F., Wang, W., & Huang, H. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2023.05.014 · Cited by 43
A review of chitosan-based nanocarriers as drug delivery systems for brain diseases: Critical challenges, outlooks and promises
Khodaverdi, K., Bakhshi, A., Mozafari, M. R., & Naghib, S. M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134962 · Cited by 45
Donepezil HCl Liposomes: Development, Characterization, Cytotoxicity, and Pharmacokinetic Study
Rajput, A., & Butani, S. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02209-9 · Cited by 42
A novel strategy for glioblastoma treatment combining alpha-cyano-4-hydroxycinnamic acid with cetuximab using nanotechnology-based delivery systems
Ferreira, N. N., Granja, S., Boni, F. I., Ferreira, L. M. B., Reis, R. M., Baltazar, F., & Gremião, M. P. D. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00713-8 · Cited by 42
Targeted nano-delivery of chemotherapy via intranasal route suppresses in vivo glioblastoma growth and prolongs survival in the intracranial mouse model
Sandbhor, P., Goda, J. S., Mohanty, B. S., Gera, P. B., Yadav, S., Chekuri, G., Chaudhari, P. R., Dutt, S., & Banerjee, R. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01220-8 · Cited by 41
Nose-to-brain co-delivery of drugs for glioblastoma treatment using nanostructured system
Ferreira, N. N., de Oliveira, E., Granja, S., Boni, F. I., Ferreira, L. M. B., Cury, B. S. F., dos Santos, L. C. R., Reis, R. M., Lima, E. M., Baltazar, F., et al. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120714 · Cited by 40
Assessment of Nasal-Brain-Targeting Efficiency of New Developed Mucoadhesive Emulsomes Encapsulating an Anti-Migraine Drug for Effective Treatment of One of the Major Psychiatric Disorders Symptoms
El-Enin, H. A. A., Mostafa, R. E., Ahmed, M. F. E., Naguib, I. A., Abdelgawad, M. A., Ghoneim, M. M., & Abdou, E. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020410 · Cited by 39

Authors: Mittal, D., Ali, A., Md, S., Baboota, S., Sahni, J. K., & Ali, J.
Affiliations: Jamia Hamdard (IN)
Corresponding author: Ali, Javed
ORCID: Ali, Asgar
Md, Shadab
Baboota, Sanjula
Ali, Javed
Venue: Drug Delivery
Publisher: Informa UK Limited
Published: 2013-10-09
Volume: 21
Issue: 2
Pages: 75-86
ISSN: 1071-7544 (ISSN-L)
1521-0464
DOI: 10.3109/10717544.2013.838713
OpenAlex: W2019126236
Cited by: 359
References: 70
Citations by year: 2026: 22 · 2025: 42 · 2024: 44 · 2023: 35 · 2022: 34 · 2021: 39 · 2020: 37 · 2019: 39 · 2018: 21 · 2017: 12 · 2016: 11 · 2015: 13 · 2014: 10
FWCI: 1.42
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Drug Delivery (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Health Sciences › Medicine › Surgery › Head and Neck Surgical Oncology
Keywords: intranasal drug delivery, nose-to-brain delivery, blood-brain barrier bypass, olfactory nerve, trigeminal nerve, olfactory epithelium, dry powder formulation, brain drug delivery, neurological disorders, Alzheimer's disease, depression, migraine, schizophrenia
MeSH terms: Administration, Intranasal, Animals, Blood-Brain Barrier, Brain, Central Nervous System Agents, Forecasting, Humans, Nasal Mucosa, Nose, Olfactory Mucosa, Drug Delivery Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Insights into direct nose to brain delivery: current status and future perspective

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks